Introduction {#s02}
============

In eukaryotes, approximately one third of the proteome is synthesized at the ER. These proteins enter the ER through a protein translocon in an unfolded state ([@bib160]). To gain activity and traffic to their final destinations, proteins residing in the secretory pathway must fold into tertiary and, in some cases, quaternary structures. To this end, myriad chaperones are recruited to stabilize folding intermediates and overcome energy barriers ([@bib10]). Protein folding in the ER is also guided by posttranslational modifications, including glycosylation, disulfide bond formation, proline isomerization, and lipidation ([@bib24]; [@bib39]).

Despite the enormous investment of cellular resources dedicated to protein folding, 12--15% of newly synthesized polypeptides in human cells and 1--5% in yeast are cotranslationally eliminated by the ubiquitin-proteasome system ([@bib53]; [@bib212]). The percentage of newly synthesized proteins in the ER degraded posttranslationally might be even higher, since these substrates may translocate inefficiently into the ER, may fail to be posttranslationally modified, or, for membrane proteins, may be unable to achieve their proper membrane topology ([@bib202]; [@bib37]; [@bib181]). These problems are exacerbated if proteins harbor disease-causing mutations that compromise protein biogenesis ([@bib72]; [@bib196]).

To counteract protein misfolding and maintain protein homeostasis, or "proteostasis," in the secretory pathway, multiple quality control (QC) mechanisms exist: ER-associated degradation (ERAD), ER-phagy, Golgi QC (GQC), and plasma membrane QC (PMQC). Each process is regulated to some degree by the unfolded protein response (UPR) and/or the heat shock response, which adjust protein synthesis, chaperone levels, and the activity of protein degradation pathways ([@bib201]; [@bib119]; [@bib155]; [@bib103]). Some misfolded proteins are subject to more than one QC pathway, and it is becoming clear that QC mechanisms can cooperate or act preferentially on some substrates over others. Regardless, if QC pathways fail, then cellular homeostasis is compromised, and cell and organism death may occur ([@bib37]; [@bib224]; [@bib175]).

In this review, we first outline the molecular mechanisms that define ERAD, ER-phagy, and GQC and then highlight the decisions that triage misfolded proteins for ERAD versus post-ER quality control (ERQC). We next discuss the interplay between ER and two post-ERQC pathways, i.e., proteasome-dependent GQC and lysosome/vacuole-dependent GQC.

ERAD: The first line of defense {#s03}
===============================

Identification of ERAD substrates {#s04}
---------------------------------

To protect against the transport of misfolded proteins through the secretory pathway, it was hypothesized that an unknown ER-resident protease could destroy misfolded proteins (reviewed in [@bib138]). Subsequent studies instead revealed the contributions of the cytosolic ubiquitin-proteasome system ([@bib185]; [@bib98]; [@bib217]; [@bib76]; [@bib82]; [@bib129]; [@bib219]). Thus, the ER membrane establishes a physical barrier that separates the ER folding and degradation machineries, protecting folding intermediates from premature degradation. Despite the immense structural and topological diversity of proteins that enter the secretory pathway, work primarily in the budding yeast, *Saccharomyces cerevisae*, revealed a conserved principle under which ERAD operates: misfolded proteins are recognized and ubiquitinated through either the ERAD-L (ERAD of substrates with misfolded lesions within the ER lumen), ERAD-C (cytoplasm), or ERAD-M (membrane) pathways, depending on the location of the folding lesion ([@bib91]; [@bib206]; [@bib33]; [@bib48]). Key players required for substrate ubiquitination are the E3 ubiquitin ligases, which in yeast are Hrd1 (ERAD-L/ERAD-M) and Doa10 (ERAD-C). However, the assignment of mammalian ERAD substrates to three ERAD classes is less straightforward due to the existence of the numerous E3 ligases that work individually and in concert ([@bib18]; [@bib42]). Nevertheless, common in both yeast and mammalian cells are chaperone- and lectin-mediated substrate recognition, energy-dependent substrate retrotranslocation from the ER, polyubiquitination, and proteasome-mediated degradation ([Fig. 1](#fig1){ref-type="fig"}).

![**The three branches of the ERAD pathway in yeast.** Lower panels in A, B, and C define the different steps during ERAD-L, ERAD-M, and ERAD-C, respectively. **(A)** ERAD-L substrates containing lumenal folding lesions (red star) and *N*-linked glycans (gray diamond) are recognized and processed by an enzyme cascade to generate an ERAD-targeting glycan (yellow diamond). Chaperones (e.g., Kar2) and lectins (e.g., Yos9) capture the substrate for transfer to the Hrd1 complex for retrotranslocation-coupled ubiquitination (purple triangle). **(B)** ERAD-M substrates containing a membrane-embedded folding lesion (red star) are recognized and ubiquitinated by the Hrd1 complex. **(C)** ERAD-C substrates containing cytosolic folding lesions are instead recognized by cytosolic chaperones (e.g., Ydj1/Hsp40 and Ssa1/Hsp70), which bridge the Doa10 ubiquitin ligase to an ERAD substrate. The three ERAD branches converge at a Cdc48-complex--dependent retrotranslocation step (D, top). The Cdc48 complex also contains Ufd1/Npl4, which interacts with ubiquitin (purple triangle). Following retrotranslocation, substrates are escorted to the 26S proteasome for degradation with the help of the Ras23 and Dsk2 shuttling factors.](JCB_201906047_Fig1){#fig1}

The best-characterized ERAD substrates are misfolded ERAD-L glycoproteins, for which recognition commonly requires both an *N*-linked glycan and a protein determinant. During glycoprotein folding, a core glycan, Glc~3~Man~9~GlcNAc~2~, is first appended to an asparagine side chain in the N-X-(S/T) consensus motif ([@bib79]). The glycan is subsequently trimmed in concert with chaperones and lectins, such as calnexin, that monitor glycoprotein folding ([@bib6]; [@bib114]). Specifically, the three terminal glucose residues are cleaved sequentially by glucosidase I and II, generating Man~9~GlcNAc~2~ ([@bib96]; [@bib84]). Another lectin, known as malectin, binds the species containing two glucoses and helps prevent the secretion of immature glycoproteins ([@bib173]). Further trimming by mannosidase I (Mns1) of the glucose-free species removes the α-1,2-mannose from the B-branch in the glycan, yielding Man~8~GlcNAc~2~ ([@bib31]; [@bib96]). In yeast, the Man~8~GlcNAc~2~ glycan is potentially shared by both folded proteins that will exit the ER in COPII (coat promoter-II) vesicles along with misfolded proteins, indicating that Mns1 fails to discriminate between these proteins ([@bib66]). To specifically generate an ERAD glycan signal, an exposed α-1,6-mannose is generated by Htm1 (EDEM in mammals; [@bib144]). In mammals, there are three Htm1 orthologues, EDEM1, EDEM2, and EDEM3, which function sequentially to convert Man~9~GlcNAc~2~ to Man~7~GlcNAc~2~ (which exposes α-1,6-mannose) in a two-step process ([@bib142]). In mammals, more extensive mannose trimming by other mannosidases has also been observed and may take place in QC vesicles ([@bib182]). These misfolded glycoproteins are captured by the Yos9 (OS-9 and XTP-3B in mammals) lectins, which also bind to hydrophobic motifs and deliver substrates to Hrd3 (Sel1L in mammals; [@bib205]). Hrd3/Sel1L is a core component of the Hrd1 complex ([Fig. 1](#fig1){ref-type="fig"}; [@bib152]; [@bib48]; [@bib226]).

In addition to a glycan, a feature in most terminally misfolded proteins and folding intermediates is an exposed hydrophobic patch that is otherwise buried in native proteins. Besides assisting substrate delivery to Hrd3 as will be discussed, the solubility of these proteins is maintained by ER-resident molecular chaperones, including an Hsp70 (Kar2 in yeast or BiP in mammals), along with Hsp40 partners ([@bib96]; [@bib27]; [@bib143]; [@bib66]). The exposure of an unpaired Cys also leads to retention in the ER ([@bib162]), thereby preventing the formation of potentially toxic disulfide-linked aggregates in later secretory pathway compartments.

More recent work suggests the involvement of another glycan-dependent event during ERAD, *O*-mannosylation ([@bib229]; [@bib227],[@bib228]). In yeast, this modification on Ser/Thr residues helps terminate futile folding cycles. Both *N*-glycan trimming and *O*-mannosylation are slow, which allows substrates to linger in the ER. In principle, this provides time for proteins to fold, but this delay may also present folding intermediates to the ERAD machinery, especially since some chaperones are involved in protein folding and turnover ([@bib156]). This conundrum was solved by the discovery of the Slp1--Emp65 complex, which protects folding intermediates from premature degradation in yeast ([@bib194]; [@bib240]).

After selection, ERAD-L substrates are delivered to the Hrd1 complex, which includes Yos9, Hrd3, Der1, Usa1, and Hrd1 ([Fig. 1](#fig1){ref-type="fig"}; [@bib33]; [@bib48]). The degradation of ERAD-M substrates utilizes a refined group of Hrd1 complex members ([@bib167]). Since the RING domain in Hrd1, which is required for ubiquitin ligase activity, resides on the cytosolic face of the ER, ERAD-L substrates must be retrotranslocated from the ER ([@bib176]). The identity of the proteinaceous "retrotranslocon" has been controversial as will be discussed in the Retrotranslocation and degradation section of this paper.

Another ubiquitin ligase, Doa10, is involved in the turnover of ERAD-C substrates (see below) and can even target select ERAD-M substrates, such as an orphaned member of the translocation channel (Sbh2) that exposes a transmembrane degron ([@bib74]). Another class of ERAD-M substrates are single-pass membrane proteins, such as unassembled α and β T cell receptor subunits, whose transmembrane domains are marginally hydrophobic. These subunits translocate into the ER lumen, where they are then recognized by BiP before being retrotranslocated ([@bib55]). Other ERAD-M substrates, including a mutated form of the translocation channel, even mislocalize to the inner nuclear membrane and are recognized and ubiquitinated by the Asi complex before proteasomal degradation. The Asi complex also seems to recognize folding lesions within the transmembrane domain ([@bib57]; [@bib106]). Together, ERAD-M substrates with diverse folding lesions are recognized by diverse pathways.

Unlike the examples discussed, some membrane proteins expose misfolded lesions in cytosolic domains. The common feature of these ERAD-C substrates is the exposure of normally buried hydrophobic patches. To prevent protein aggregation, cytosolic chaperones, including Hsp70, Hsp40, nucleotide exchange factors, Hsp90, and small heat shock proteins, are engaged ([@bib91]; [@bib238]; [@bib3]; [@bib77]; [@bib148]; [@bib73]; [@bib195]). Hsp70 and Hsp40 not only prevent protein aggregation but also facilitate the association between an E3 ubiquitin ligase and an ERAD-C substrate ([@bib136]). Although it is poorly understood how a single chaperone can dictate different fates (protein maturation versus degradation), prolonged chaperone engagement of ERAD-C substrates might be sufficient to recruit an E3 ubiquitin ligase (i.e., Doa10) to modify and retrotranslocate these substrates.

Substrate ubiquitination {#s05}
------------------------

The ubiquitination of ERAD substrates requires a cascade of enzymes, including an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin ligase ([@bib145]). For the Doa10-dependent ubiquitination of ERAD-C substrates, two E2s, Ubc6 and Ubc7, are involved ([Fig. 1](#fig1){ref-type="fig"}). Ubc6 can attach a single ubiquitin not only to Lys but also to hydroxylated amino acids, which act as a primer for Ubc7-dependent polyubiquitination ([@bib218]). In conjunction with Doa10, another ligase that is responsible for *N*-end rule degradation (Ubr1) contributes to the turnover of select ERAD-C substrates ([@bib192]; [@bib154]). In contrast to the E2 requirements for ERAD-C, only Ubc7 appears to be required for ERAD-L and ERAD-M, which works in concert with Hrd1. To this end, Ubc7 is tethered to the ER by Cue1, which facilitates ubiquitin loading ([@bib132]). For the degradation of an ERAD-L and ERAD-M substrate in mammals, mixed K-48/K-11 polyubiquitin chains are appended, which facilitates interaction with downstream components of the ERAD machinery ([@bib117]). The discrimination of a subset of ERAD substrates, such as CD4, may employ a different mechanism, termed deubiquitinase sharpening. In this case, the degree of deubiquitinase-mediated rescue of potential ERAD substrates, rather than chaperone-mediated E3 activity per se, controls the rate of substrate removal ([@bib241]). More generally, deubiquitinases regulate the timing of ERAD by trimming polyubiquitin chains on misfolded proteins ([@bib20]) and maintain productive protein folding ([@bib1]; [@bib56]). Nevertheless, because some polytopic membrane proteins in the ERAD-M family may bear multiple folding lesions ([@bib28]), different branches of the ERAD pathway can cooperate with one another during substrate recognition and ubiquitination. The hierarchy of the decision-making process during the degradation of these more complex substrates is unknown.

Retrotranslocation and degradation {#s06}
----------------------------------

For substrates with lumenal lesions (i.e., those handled by the ERAD-L pathway), Sec61 and Hrd1 are prime candidates for the ERAD retrotranslocon. Based on its function as the ER translocation channel, Sec61 was thought to act in reverse and function as a retrotranslocon. Evidence supporting this hypothesis includes experiments demonstrating interaction between Sec61 and ERAD substrates as well as the proteasome ([@bib221]; [@bib102]; [@bib172]). In addition, Apolipoprotein B is retrotranslocated and targeted for degradation when forward translocation through Sec61 is interrupted ([@bib133]), indicating that the two functions for this channel, translocation and retrotranslocation, can be uncoupled. More recent evidence favors the Hrd1 ubiquitin ligase as the retrotranslocon for other ERAD substrates. First, the function of this eight transmembrane protein requires oligomerization, and Hrd1 interacts with substrates at an early retrotranslocation stage ([@bib87]; [@bib34]). Additional evidence emerged from a reconstitution assay in which substrate retrotranslocation was recapitulated in proteoliposomes containing only Hrd1. In this case, retrotranslocation also required Hrd1-dependent autoubiquitination ([@bib11]). The identity of Hrd1 as a retrotranslocon was corroborated by a cryo-electron microscopy structure of Hrd1 in complex with Hrd3 ([@bib176]). Five of the eight transmembrane segments in Hrd1 form a funnel that extends almost completely from the cytosol to the lumen. Moreover, the aqueous cavity formed by Hrd1 is reminiscent of that formed by Sec61.

Another candidate for the retrotranslocon was Der1, a multispanning membrane protein that helps eliminate some ERAD substrates ([@bib109]; [@bib206]; [@bib131]). As a component of the Hrd1 complex, Der1 receives ERAD-L substrates from Yos9/Hrd3 and transfers them to Hrd1 ([@bib87]; [@bib131]). In one study, Derlin-1 (the Der1 homologue) facilitated the retrotranslocation of a soluble substrate from mammalian microsomes ([@bib209]). However, the substrate is degraded in a ubiquitin-independent manner, which may bypass the requirement for an alternate retrotranslocon ([@bib219]). Other evidence indicates that Der1 intimately contacts ERAD substrates as they exit the ER, perhaps by facilitating transmembrane domain solubilization ([@bib131]).

Do ERAD-M substrates also use Hrd1 as the retrotranslocon? The identification and extraction of membrane proteins with folding lesions within the lipid bilayer is challenging. To date, HMG-CoA (hydroxymethylglutaryl coenzyme A) reductase (Hmg2 in yeast) is the best-characterized ERAD-M substrate ([@bib189]; [@bib100]). This enzyme catalyzes the rate-limiting step during sterol biosynthesis, and thus, the reductase is stringently regulated by sterols and a sterol-dependent chaperone ([@bib216]). The interaction between Hrd1 and Hmg2 appears to be direct ([@bib169]), and for many years, it was assumed that Hrd1 facilitates Hmg2 retrotranslocation. More recent data instead implicate a Der1 homologue, Dfm1, as a retrotranslocon ([@bib137]). In contrast, it remains unclear if ERAD-C substrates are extracted directly from the ER membrane in the absence of a retrotranslocon or whether the Doa10 ubiquitin ligase, which contains 14 transmembrane domains, is used ([@bib112]; [@bib161]).

During retrotranslocation from the ER or the ER membrane, lumenal disulfide bonds are broken by a reductase, which facilitates egress through the retrotranslocon ([@bib204]). The action of a cis-trans Prolyl isomerase and the removal of an *N*-linked glycan can also contribute to retrotranslocation and/or degradation efficiency ([@bib19]; [@bib83]). Ubiquitinated substrates are then transferred to the 26S proteasome via the Cdc48 complex (or the p97 complex in mammals; [@bib25]; [@bib97]; [@bib235]). Cdc48 recruitment to the ER is facilitated by Ubx2 ([@bib139]; [@bib178]). Ultimately, the Cdc48 complex provides the driving force for retrotranslocation via ATP hydrolysis ([@bib13]; [@bib234]; [@bib159]) and pulls or segregates ubiquitinated substrates out of the ER membrane and into the cytosol before proteasomal degradation ([@bib22]).

Cdc48 is a member of the ATPases associated with various cellular activities (AAA+ ATPase) family and contains a central pore, which is reminiscent of related protein-unfolding AAA+s, such as Hsp104 and ClpB ([@bib135]; [@bib65]). During retrotranslocation, polyubiquitinated substrates bind the Cdc48--p97 complex via Ufd1/Npl4, and an unfolded loop in the substrate reaches the central pore in Cdc48--p97 ([@bib21]; [@bib22]). Upon ATPase-dependent entry into the pore, Ufd1/Npl4 binding is weakened by ubiquitin chain trimming, which facilitates further threading through the pore. Polyubiquitin chain trimming is catalyzed by an associated deubiquitinating enzyme. Released substrates with ubiquitin chains that are too short to be degraded by the proteasome are modified by another Cdc48 cofactor, Ufd2, which is an E4 ubiquitin elongation enzyme ([@bib110]). A recent study indicates that Cdc48 initiates retrotranslocation via the unfolding of a substrate-appended ubiquitin molecule, which enters the Cdc48 pore ([@bib203]).

ERAD substrate delivery to the proteasome is facilitated by shuttling factors that contain both ubiquitin- and proteasome-binding domains ([@bib107]; [@bib130]). In higher eukaryotes, a chaperone holdase complex, which contains Bag6, associates with retrotranslocated ERAD substrates to prevent aggregation ([@bib213]). Chaperone holdases are especially critical for retrotranslocated membrane proteins since they contain hydrophobic transmembrane domains and are consequently aggregation prone. Since yeast lack Bag6, Hsp104 facilitates the solubilization and retrotranslocation of aggregation-prone ERAD substrates ([@bib157]; [@bib51]).

Protein QC versus quantity control {#s07}
----------------------------------

In addition to misfolded proteins, some native proteins deemed unnecessary are turned-over by ERAD. For the quantity control of these substrates, adaptor protein binding, ligand binding, and/or the display of a degron is essential.

As outlined previously, Hmg2 is degraded in response to the accumulation of specific sterols. When sterol levels are high, Hmg2 adopts a conformation that is recognized by Hrd1--Hrd3 ([@bib200]). On the contrary, depleted lipids trigger Apolipoprotein B degradation, since the protein fails to translocate fully into the ER and assemble into a lipoprotein particle ([@bib50]). An example of ligand-dependent quantity control is the yeast cadmium exporter Pca1, which contains a cytosolic ERAD-targeting signal that becomes exposed in the absence of cadmium. When cadmium levels rise, Pca1 is stable ([@bib2]). An example of adaptor-mediated quantity control is Ypf1, which signals the ERAD of a yeast zinc transporter under zinc-replete conditions ([@bib8]). Another example of adaptor-mediated quantity control occurs when the ERAD pathway is hijacked by a virus. The human cytomegalovirus encodes two membrane adaptors, US2 and US11, which bind newly synthesized major histocompatibility complex (MHC) class I molecules and recruit the ERAD machinery ([@bib220]; [@bib187]). Cell-surface display of MHC class I is reduced, thereby disabling the host immune response. A similar strategy is used by the HIV-encoded adaptor Vpu, which directs CD4 to the proteasome ([@bib63]; [@bib177]). Very recently, a link between cancer and ERAD quantity control was uncovered: the antidiabetic drug metformin signals the destruction of an oncogenic ligand, which consequently attenuates tumor growth ([@bib35]). Together, it is probable that new examples of ERAD-dependent quantity control will emerge, along with additional examples of QC, especially as expanding clinical and genomic databases are leading to the identification of previously undiscovered disease-associated proteins that access the secretory pathway.

ER-phagy: A brother-in-arms for the ERAD pathway {#s08}
================================================

While most misfolded proteins in the ER are efficiently handled by the ERAD pathway, the diameter of the pore in the retrotranslocon may preclude misfolded oligomeric or aggregated proteins from being exported from the ER. Because these substrates are toxic, the ER is equipped with another mechanism to protect homeostasis, ER-phagy, and links between ER-phagy and diseases are continually emerging. One study classified yeast ER-phagy as micro-ER-phagy and macro-ER-phagy ([@bib122]), and a receptor-mediated degradation pathway for misfolded proteins generated in the ER was recently termed ER-to-lysosome--associated degradation (ERLAD; reviewed in [@bib60]; [@bib222]).

The term ER-phagy was first used upon the discovery of ER whorls, which arise after UPR-associated lipid synthesis in yeast ([@bib16], [@bib17]). Later studies indicated that ER-phagy is induced by nitrogen starvation, rapamycin treatment, and protein aggregation and uses the core autophagy machinery ([@bib71]). ER-phagy also disposes of ERAD-resistant misfolded proteins ([@bib60]). The discovery of various ER-phagy receptors ([Fig. 2](#fig2){ref-type="fig"}) highlights the potential for substrate selection. Each receptor contains a domain that facilitates interaction with an autophagy-requiring factor, Atg8/LC3. However, many receptors lack lumenal domains, so their ability to identify lumenal cargo requires an adaptor.

![**ER-phagy in yeast and mammals.** ER-phagy receptors reside in distinct ER subdomains (yeast, left; mammals, right). ER-phagy receptors concentrate cargo in an ER subdomain via interaction with Atg8 (yeast) or LC3/GABARAP (mammal) in the growing autophagic membrane, the phagophore. ER-phagy substrates are next enclosed in a double-membrane-bound autophagosome, which fuses with the lysosome/vacuole. In yeast, the UPR (black lightning bolt) can give rise to ER whorls, which are nonselectively delivered to the vacuole. In mammals, Sec62 helps reestablish ER homeostasis after UPR induction.](JCB_201906047_Fig2){#fig2}

In yeast, Atg40 localizes primarily to the cortical and cytoplasmic ER, resulting in autophagic sequestration of ER subdomains. Atg40 contains an Atg8 interacting motif, allowing for Atg8 engagement of the phagophore membrane ([@bib134]). The phagophore serves as a precursor to autophagosomes, which ultimately fuse with lysosomes via endosomes and multivesicular bodies (MVBs; see below). Nitrogen starvation or rapamycin enhances Atg40 expression, providing a means to induce ER-phagy. These conditions, along with the expression of an aggregation-prone ERAD substrate, also induce the expression of an alternate COPII subunit, Lst1, which functions with Atg40 to select ER-phagy sites. An Lst1 homologue, SEC24C, similarly marks ER-phagy sites in mammals ([@bib45]).

The identification of ER-phagy receptors in mammals, including FAM134B, RTN3, Sec62, cell-cycle progression gene 1 (CCPG1), ATL3, and TEX264, has advanced our understanding of ER-phagy ([@bib105]; [@bib64]; [@bib70]; [@bib184]; [@bib5]; [@bib38]; [@bib40]). For example, FAM134B mediates starvation-induced ER-phagy in mammalian cells and localizes at the edge of ER sheets via a reticulon homology domain, promoting membrane curvature during autophagosome formation ([@bib105]). The presence of an LC3-interacting region (LIR) motif in FAM134B recruits LC3 (the orthologue of yeast Atg8) and/or GABARAP (Gamma-aminobutyric acid receptor-associated protein) at the limiting membrane of growing phagophores.

An expanding group of misfolded proteins has been identified as FAM134B cargo. Notably, mutations in type I procollagen (PC1) or the Hsp47 collagen chaperone form ERAD-resistant protein aggregates, which are eliminated by ER-phagy or ERLAD in a FAM134B-dependent manner ([@bib94]; [@bib61]; [@bib58]). In at least one case, FAM134B-dependent recognition requires a chaperone-like lectin in the ER, calnexin. This is essential, since FAM134B lacks an ER lumenal domain. Another FAM134B substrate is a misfolded form of the Niemman--Pick type C disease protein, but unlike PC1, this substrate is degraded by both ERAD and ER-phagy ([@bib67]; [@bib179]). Interestingly, FAM134B is cleaved by a protease encoded in the Zika and Dengue viral genomes ([@bib116]). It will be important to identify other lumenal factors that contribute to substrate recognition and determine whether additional pathogens modulate ER-phagy efficiency.

The ER-phagy receptor RTN3 also contains a reticulon homology domain ([@bib232]). During amino acid starvation, RTN3 oligomerizes to engage and cluster LC3, which forms autophagosomes at ER tubules ([@bib70]). ATL3 also functions at ER tubules ([@bib121]; [@bib38]). Although ATL3 and RTN3 drive autophagosome formation and interact with different ATG8 family members, RTN3 overexpression restores ER-phagy upon loss of ATL3 ([@bib38]). In contrast, a receptor for "recovER-phagy" is an LIR motif-containing protein, Sec62, which in this case acts independently of its role during protein translocation ([@bib64]). RecovER-phagy resets ER volume and content after ER stress and employs the autophagy core machinery.

Unlike the receptors mentioned above, CCPG1 contains both LIR and FIP200-interacting regions, which bind independently to LC3 as well as FIP200, another component that associates with the autophagy machinery ([@bib184]). During ER stress, CCPG1 expression is up-regulated to remove portions of the peripheral ER to reduce protein aggregation. It is unknown if CCPG1 specifically recognizes aggregated or misfolded proteins.

Recently, TEX264 was identified as a starvation-induced ER-phagy receptor that functions at three-way junctions in the ER ([@bib5]; [@bib40]). TEX264 contains a long disordered region between its membrane domain and the LIR motif that is required for ER-phagy ([@bib40]). Compared with other identified receptors, TEX264 binds with greater efficiency to LC3 and GABARAP. In addition, TEX264 is expressed more ubiquitously and probably accounts for half of all ER-phagy flux during starvation ([@bib40]). Overall, even though the identification of these ER-phagy receptors has helped define the nature of cargo selection, how the ER-phagy machinery degrades most receptor-bound cargo proteins remains an important open question ([@bib222]).

Finally, other pathways that handle misfolded ER proteins and use autophagy-associated factors have been identified. For example, α-1 antitrypsin-Z (AT-Z), which is an aggregation-prone and disease-associated substrate, is destroyed by ERAD as well as autophagy in yeast ([@bib113]). In mammalian cells, AT-Z can be sorted for lysosome-dependent degradation by the ER-phagy receptor FAM134B, but this pathway is distinct from the canonical ER-phagy pathway and thus represents an example of an ERLAD substrate ([@bib61]). Also, in contrast to the FAM134B-dependent targeting of PC1, another report suggested that collagen was sequestered at ER exit sites marked by COPII components along with components of the autophagy machinery ([@bib147]). Based on image analysis, it was proposed that the lysosome contacts these sites and directly engulfs collagen. The authors suggested that this autophagosome-independent process may involve the recognition of ubiquitinated COPII components that are otherwise used to enlarge COPII vesicles ([@bib99]).

GQC: A means to catch ER escapees {#s09}
=================================

Secretory proteins exit the ER in COPII vesicles through bulk flow or a receptor-mediated process ([@bib12]; [@bib69]). Although high levels of secretory proteins could overwhelm ER retention mechanisms, autoregulation of ER export monitors and regulates the flux of folded cargos from the ER in mammalian cells ([@bib193]). In response to increased secretory protein production, autoregulation of ER export components are activated to facilitate cargo export and attenuate protein synthesis.

The Golgi apparatus, the next organelle encountered by secretory proteins after ER exit, functions as a protein modification factory, chemically altering substrates via glycosylation, acetylation, phosphorylation, sulfation, palmitoylation, and methylation. Some substrates are proteolytically activated. In addition, the Golgi serves as a QC checkpoint ([@bib7]; [@bib153]). Collectively, these events have been referred to as post-ERQC, ERLAD, or GQC, although there are some distinctions among these pathways. Indeed, a growing number of misfolded proteins escape ERAD and are delivered to the lysosome/vacuole for degradation after being selected in the Golgi. Based on where they are degraded, we propose that GQC can be differentiated into proteasome-targeted GQC and lysosome/vacuole--targeted GQC ([Fig. 3](#fig3){ref-type="fig"}). Regardless of how these events are defined, there are critical open questions in this field of research. Why do some substrates avoid ERAD but are instead targeted for GQC? What are the structural or other features that distinguish between these substrates? What role does ER--Golgi recycling play in substrate degradation? Does the entire population or only a subset of misfolded proteins traffic to the Golgi before being retrieved and degraded? Can drugs be developed to rescue disease-causing proteins that access later steps in the secretory pathway before being degraded?

![**The GQC pathway in yeast.** Misfolded proteins targeted for GQC are transported to the cis-Golgi via COPII vesicles. Proteasome-targeted GQC: ER chaperones (e.g., Kar2 \[in pink\]) and retrieval receptors (in blue) in the cis-Golgi bind and retrieve misfolded proteins to the ER in COPI vesicles. These substrates are eliminated by ERAD-L. Lysosome/vacuole--targeted GQC: misfolded proteins that migrate to the trans-Golgi are sorted by the ESCRT/MVB pathway via Vps10 (green) or a ubiquitin ligase (e.g., Tul1). Following sorting, misfolded proteins are delivered to the vacuole.](JCB_201906047_Fig3){#fig3}

Beyond the Golgi, select misfolded or dispensable proteins that are instead identified exclusively at the plasma membrane and delivered to the lysosome/vacuole are handled by the PMQC machinery. Interestingly, several elements of the PMQC pathway resemble those used during QC in the ER and Golgi. Due to space considerations, the reader is referred to reviews on this topic ([@bib146]; [@bib124]).

Proteasome-targeted GQC {#s10}
-----------------------

Evidence from both yeast and mammalian studies support the involvement of the Golgi during ERAD. In budding yeast, efficient elimination of select ERAD-L substrates requires ER, exit because blocking ER-to-Golgi trafficking inhibited ERAD ([@bib30]; [@bib207]; [@bib197]; [@bib206]). In fact, Erv29, which cycles between the ER and Golgi, was identified as the COPII vesicle cargo receptor for two such substrates ([@bib30]; [@bib207]). Other misfolded proteins with mutated transmembrane domains are specifically returned to the ER from the Golgi via a retrieval receptor, Rer1 ([@bib118]; [@bib170]). Because Erv29 and Rer1 fail to distinguish between folded and misfolded cargo, the escaped ERAD substrates are probably packaged into COPII and retrieved via COPI vesicles ([@bib207]) along with proteins that normally reside in the ER and must be retrieved.

In mammalian cells, unassembled MHC class I heavy-chain molecules expose polar residues in the transmembrane domain that are otherwise shielded by a partner, β~2~ microglobulin ([@bib90]). Instead of being retained in the ER, unassembled MHC class I molecules advance to the cis-Golgi before retrieval and ERAD ([@bib89]). A similar result was evident for the MHC class II β subunit, which cycles between the Golgi and ER. Accelerated proteasomal degradation of the β subunit upon brefeldin A treatment, which redistributes Golgi components to the ER, is consistent with Golgi transport ([@bib52]). COPI vesicle transport also plays an important role in retrieving unassembled TCRα (T cell receptor alpha subunit) to the ER ([@bib230]). In other cases, the ER chaperone BiP in conjunction with the K/HDEL receptor retrieves aberrant proteins, such as an unassembled TCRα subunit ([@bib75]; [@bib230]). Consistent with data in yeast, the human orthologue of Rer1 also returns misfolded proteins with lesions in a transmembrane domain to the ER ([@bib231]; [@bib26]). In contrast, when a misfolded GPI-anchored protein leaves the ER and then escapes GQC, it is handled by PMQC but remains bound to ER chaperones ([@bib171]; [@bib239]).

Regardless of the mechanism by which substrates are retrieved, proteasome-targeted GQC most likely takes place in the cis-Golgi or perhaps in the ER-Golgi intermediate compartment. First, the K/HDEL retrieval receptor in yeast, Rer1, and Erv29 primarily reside in the cis-Golgi under steady-state conditions. Second, several proteasome-targeted GQC substrates fail to acquire Golgi modifications, which occurs in the medial Golgi in mammalian cells ([@bib89]; [@bib52]; [@bib95]). Because ER retrieval is independent of substrate ubiquitination or the MVB pathway (see below), proteasome-dependent GQC is a gatekeeper that prevents ERAD substrates from entering later steps in the secretory pathway.

Lyosome/vacuole--targeted GQC {#s11}
-----------------------------

The previous use of the term GQC referred to an event that delivers misfolded proteins for lysosomal degradation. In this article, we define lysosome/vacuole--targeted GQC to describe this pathway, one that sorts misfolded proteins for lysosomal or vacuolar degradation in higher cells and in yeast, respectively. Data have primarily arisen from studies in yeast and revealed two routes to steer misfolded proteins from the Golgi to the lysosome/vacuole: receptor-mediated sorting and ubiquitin ligase-mediated sorting.

Receptor-mediated GQC {#s12}
---------------------

The proteinase A and carboxypeptidase Y hydrolases are sorted to the vacuole from the Golgi via clathrin-coated vesicles ([@bib23]), but loss of Vps10 results in secretion ([@bib126]; [@bib43]). In addition to these wild-type cargo, Vps10 also recognizes and sorts misfolded proteins for vacuolar degradation ([@bib86]; [@bib85]; [@bib210]). Both deletion of *VPS10* and overexpression of a misfolded substrate lead to secretion, indicating a saturable process ([@bib86]). How Vps10 recognizes folded versus misfolded proteins remains unknown, but these substrates may engage different sites on Vps10 ([@bib101]).

A similar sorting mechanism was subsequently discovered in mammalian cells, and a key factor in the sorting of some aggregation-prone substrates is sortillin. Sortilin is a Vps10 orthologue that resides primarily in the Golgi and plasma membrane and mediates lysosomal cargo sorting ([@bib140], [@bib141]; [@bib115]; [@bib4]). Similar to its yeast counterpart, sortilin also regulates the lysosomal sorting of misfolded proteins, such as aggregated GPP130, which is induced by manganese ([@bib199]; [@bib208]). Interestingly, while oligomerization/aggregation is sufficient to trigger lysosomal degradation, trafficking is sortilin independent, suggesting that protein aggregation is necessary, but not sufficient, for sortilin-mediated sorting. The finding that sortilin recognizes protein aggregates in the Golgi for lysosomal delivery is reminiscent of a study in which it was shown that furin aggregation led to lysosomal delivery ([@bib225]). Similarly, protein aggregation in the trans-Golgi was recently observed, and the aggregates were sequestered in a specific compartment in the endo/lysosomal pathway ([@bib80]). The structural features and machinery that specify Vps10/sortilin-dependent GQC are unclear.

Ubiquitin ligase--mediated GQC {#s13}
------------------------------

In yeast, two ubiquitin ligases in the Golgi recognize misfolded proteins for degradation in the lysosome: Tul1 and Rsp5 ([@bib163]; [@bib214]). After ubiquitination, misfolded membrane proteins are ferried concomitant with an inward budding process that forms intraluminal vesicles ([@bib150]). During this event, ESCRT (endosomal sorting complexes required for transport) is recruited to invaginate the endosomal limiting membrane. ESCRT-0 is first recruited by binding ubiquitin on substrates and directs the assembly of downstream complexes. Next, ESCRT-I clusters ubiquitinated proteins and bridges ESCRT-0 and ESCRT-II. ESCRT-II has high affinity for endosome-enriched phospholipid phosphatidylinositol-3-phsophate and is assembled on the late endosomal membrane. ESCRT-III is then recruited and oligomerizes to induce inward budding and intraluminal vesicle invagination. Finally, an ATPase, Vps4, strips ESCRT components and directs membrane scission ([@bib81]; [@bib41]). Late endosomes with intraluminal vesicles are termed MVBs, which fuse with the lysosome/vacuole for cargo delivery ([@bib150]).

The substrates for Tul1 contain polar residues in membrane-spanning domains. Tul1 functions with the ubiquitin-conjugating enzyme, Ubc4, to modify cytosolic domains on misfolded substrates, thereby acting as a sorting signal for the MVB pathway. Two wild-type proteins, CPS1 and Phm5, also possess polar residues in the membrane-spanning domain and are similarly ubiquitinated and delivered to the vacuole where they function. The scope of Tul1 substrates is expanded after stress ([@bib49]).

Tul1 was also identified as a component of the Dsc complex in fission yeast, and the organization of this complex mirrors that of the Hrd1 complex ([@bib190], [@bib191]). With one exception, each component exists in budding yeast, and the employment of Cdc48 suggests that a unique form of GQC is at play, one that complements the ESCRT and ERAD pathways ([@bib190]; [@bib174]). For example, when ergosterol or oxygen is depleted, the fission yeast Dsc complex binds ubiquitinated SREBP, which drives proteasome recruitment. After selective cleavage, a cytosolic transcriptional factor is produced that activates genes required for lipid metabolism ([@bib190]). How the Dsc complex recognizes its substrates and how the transcription factor domain in SREBP is protected from being completely degraded are unknown.

Interestingly, specific partners recruit the Tul1-containing complex to different organelles ([@bib120]). For example, Gld1 directs the Dsc complex to the Golgi and endosome, whereas Vld1 targets the complex to the vacuolar membrane ([@bib233]). Therefore, Tul1 is a versatile E3 ligase that complexes with different subunits to protect protein fidelity and mediate quantity control at various locations in the late secretory pathway.

Rsp5 is the other versatile ligase involved in lysosome/vacuole--targeted GQC but is primarily known for its role as a trigger for the ubiquitin-dependent down-regulation of membrane proteins at the plasma membrane ([@bib14]; [@bib125]). Rsp5 even clears mislocalized vacuolar membrane proteins ([@bib168]). Regardless of whether it acts during QC or to regulate membrane proteins, Rsp5 recognizes a PPXY motif in substrates or substrate-binding adaptors. Like Tul1, adaptors residing in different organelles deliver Rsp5 to the plasma membrane, endosomes, the vacuole, or the Golgi in yeast ([@bib14]; [@bib168]). For example, Rsp5 is recruited by the Bul1 and Bul2 adaptors to ubiquitinate misfolded membrane proteins for subsequent vacuole delivery ([@bib36]; [@bib123]; [@bib151]). An obligate GQC substrate, Wsc1\*, is another Rsp5 substrate routed from the Golgi to the vacuole ([@bib210]; [@bib214]). The absence of a PPXY motif on Wsc1\* suggests the existence of an as-yet-unidentified adaptor. Rsp5 also determines the fate of overexpressed ERAD substrates that escape the ER and advance to the Golgi but are then delivered to the vacuole ([@bib78]; [@bib186]), as well as plasma membrane transporters in response to environmental changes ([@bib47]; [@bib62]). Overall, Rsp5 disposes of misfolded membrane proteins in the Golgi and dispensable transporters, the latter of which is reminiscent of ERAD quantity control.

Unlike Rsp5, members of the homologous NEDD4 family of ubiquitin ligases in mammalian cells are involved in neither GQC nor PMQC. Instead, these enzymes induce the endocytosis of plasma membrane proteins and subsequent hand-off to the MVB pathway ([@bib165]). Channels regulated by NEDD4 and its relatives include the epithelial sodium channel and voltage-gated sodium channels, along with the insulin-like growth factor and TGFβ signaling pathway receptors ([@bib188]; [@bib59]; [@bib32]; [@bib166]).

In sum, the Golgi is armed with two QC checkpoints to destroy misfolded proteins that advance beyond the ER: proteasome-targeted GQC, which is initiated in the cis-Golgi, and lysosome/vacuole--targeted GQC, which most likely takes place in the trans-Golgi. Based on ill-defined criteria, GQC substrates are returned for ERAD via cis-Golgi resident receptors or directed for lysosomal degradation, which requires the Vps10/sortillin receptor (e.g., as seen for misfolded lumenal/soluble proteins) or a ubiquitin ligase complex (e.g., as seen for misfolded membrane proteins).

Cooperation among ERAD, ER-phagy, and GQC {#s14}
=========================================

Competition and backup pathways {#s15}
-------------------------------

Although the ERAD machinery monitors the fidelity of protein folding and clears most misfolded proteins, substrate selection is restricted by several biochemical properties. Aggregation propensity, the severity of a mutation, the site and nature of a folding lesion, the kinetics and thermodynamics of folding, and the rate at which a protein exits the ER constrain ERAD ([@bib223]). In some cases, a substrate may avoid ERAD simply because it fails to bind a specific chaperone ([@bib44]; [@bib210]). Consequently, ER-phagy and GQC expand both the ability and capacity of the ER to recognize and destroy misfolded proteins.

Substrates for proteasome-targeted GQC or lysosome/vacuole--targeted GQC undergo anterograde trafficking from the ER to Golgi, which often requires an ER exit sequence ([@bib108]; [@bib104]). However, prolonged chaperones engagement (e.g., with BiP and/or calnexin) may distinguish proteasome-targeted GQC substrates from lysosome/vacuole--targeted GQC substrates. Proteasome-targeted GQC substrates possess both a functional ER exit signal and a misfolded lesion that signals ERAD, but lysosome/vacuole--targeted GQC substrates may display more subtle lesions and contain an ER exit signal ([@bib163]; [@bib210]; [@bib214]). For misfolded protein substrates that display both an ERAD signal and an ER exit signal, the ERAD and ER exit machineries compete ([@bib108]). Conversely, when ERAD is compromised, some misfolded substrates with functional exit signals traffic beyond the ER more efficiently ([@bib186]; [@bib108]; [@bib211]). Compromising ERAD activity can also increase ER exit ([@bib108]; [@bib215]). Furthermore, under specific conditions when a soluble ERAD substrate is overexpressed, ERAD becomes saturated, resulting in Golgi and then lysosome/vacuole delivery ([@bib186]).

Most lysosome/vacuole--targeted GQC substrates contain folding lesions in the lumenal domain or a transmembrane domain. This observation is consistent with the finding that ERAD substrates with lumenal lesions can advance to the Golgi before being returned to the ER, while those with cytosolic folding lesions are retained in the ER ([@bib206]). Cytosolic folding lesions may disturb the presentation of an ER exit signal, and cytosolic chaperones may outcompete components required for COPII-mediated ER exit. Recently, we reported on a novel substrate with a cytosolic folding lesion that is degraded by both ERAD and vacuole-targeted GQC. We also showed that substrate aggregation alters the balance between ERAD and vacuole-dependent degradation in yeast ([@bib195]).

In comparison to GQC, ER-phagy might handle more severely misfolded substrates that cannot be disposed of by ERAD due to their aggregation state or the absence of an ERAD signal, which in most cases remains mysterious. Protein misfolding and aggregation could also bury ER exit signals, preventing anterograde transport. Because calnexin plays a role in ERAD and recruits FAM134B ([@bib58]), two distinct QC machineries, ERAD and ERLAD, which can rely on FAM134B and ATG-associated vesicle transport, are linked by calnexin. Other substrates are simultaneously routed for ERAD and ER-phagy (e.g., [@bib179]; [@bib46]). The identification of a detergent-soluble protein degraded in the lysosome, which forms ER puncta that colocalize with an autophagy receptor and requires autophagy--associated proteins, suggests that aggregate-free misfolded substrates are also targeted for ER-phagy ([@bib88]).

The UPR: A unifying principle {#s16}
-----------------------------

When ERAD is unable to maintain ER homeostasis, the UPR is induced. As a result, protein translation is attenuated, the ER expands, and protein folding, ERAD, ER-phagy, and GQC are enhanced ([@bib201]; [@bib236], [@bib237]; [@bib183]; [@bib184]; [@bib103]). In turn, ERAD controls the levels of some UPR components ([@bib92]), and factor required for the ERAD of glycosylated substrates are induced by the UPR. One such component is stabilized by a partner ([@bib198]). Other ERAD components induced by the UPR include Hrd1, Der1, Hrd3, Ubc7, and Erv29, the last of which transports both folded and misfolded cargo. Although the expression of Rer1, the retrieval receptor for proteasome-targeted GQC, is UPR-independent, the loss of Rer1 induces ER stress in yeast and worms ([@bib68]). Tul1, which is required for receptor-mediated GQC, is also induced by the UPR ([@bib164]; [@bib201]; [@bib163]), as is autophagic flux ([@bib180]). In metazoans, the PERK-eIF2α branch of the UPR enhances autophagy ([@bib9]), and the ER-phagy receptor CCPG1 is induced by ER stress ([@bib184]). A conserved Atg8-binding adaptor, Ubx5, was recently identified that delivers mutated, inactive Cdc48/p97 for autophagic degradation, which would otherwise compromise ERAD ([@bib128]). Another ERAD component, the proteasome itself, also becomes an autophagy substrate when inactivated ([@bib127]). Overall, the machineries employed by ERAD, ER-phagy, and GQC are stress inducible, suggesting cooperative orchestration of ER proteostasis ([Fig. 4](#fig4){ref-type="fig"}).

![**The fates of misfolded proteins in the ER.** Most misfolded proteins in the ER are eliminated by ERAD via the ubiquitin-proteasome system. Some misfolded proteins exit the ER and are sorted to the lysosome/vacuole for degradation. Other misfolded proteins are transported to the lysosome/vacuole for degradation via ER-phagy. The three QC machineries act coordinately to safeguard ER proteostasis and are induced by the UPR (defined by red text).](JCB_201906047_Fig4){#fig4}

Concluding remarks {#s17}
==================

We have highlighted key pathways that maintain proteostasis in the early secretory pathway, but our current knowledge base is restricted by the field's study of select experimental models and a fraction of the universe of substrates that might be targeted by these pathways. With growing interest in the QC field, and the isolation of an expanding cadre of substrates and methods, these limitations will ultimately be overcome. A number of related pathways have also emerged; it was recently demonstrated that a UPR- and chaperone-dependent "reflux" of folded proteins from the ER to the cytosol occurs in yeast ([@bib93]).

One open question is whether the UPR is the only mechanism that coordinately regulates the ERAD, ER-phagy, and/or GQC pathways. Downstream responses triggered by the UPR were identified when cells are treated with poisons that severely compromise protein folding, but more subtle and diverse responses are apparent upon the expression of distinct misfolded proteins ([@bib29]; [@bib15]). Furthermore, overexpression of TFEB, which increases autophagy and lysosomal function, remedies liver toxicity associated with AT-Z (see above), which is degraded by both ERAD and the lysosome ([@bib149]). These data suggest that alternate signal transduction pathways might be harnessed to treat diseases associated with early secretory pathway QC. Moreover, silencing distinct chaperones in the ER, which should globally compromise folding, leads to a UPR-independent phenomenon that alters the levels of other chaperones ([@bib54]). More trivially, inhibition of one pathway has indirect consequences on another pathway. For example, autophagy inhibition increases the levels of p62, a receptor for ubiquitinated autophagy cargo. The resulting rise in p62 delays delivery of proteasome-targeted substrates ([@bib111]).

Another open question is whether the decision between ERAD versus other pathways is made only within the ER. Mutant forms of CFTR, which are associated with cystic fibrosis, use some of the same QC factors for ERAD and PMQC ([@bib146]). Thus, it is possible that misfolded proteins are identified and tagged with chaperones in the ER, which signals QC events later in the secretory pathway. In addition, components associated with glycan QC can migrate to an ERQC compartment, which is distinct from the ER and potentially isolates the ER folding and degradation machineries ([@bib182]). In the future, it will be important to determine how this compartment interfaces with the ER-phagy and GQC pathways.

Finally, a critical undertaking will be to translate discoveries to animal models. Some studies have examined how ERAD defects lead to specific pathologies and modulate physiological responses and signaling pathways in mice ([@bib158]). The development of new animal models in which ERAD, ER-phagy, and GQC can be studied is increasingly vital.
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